Managed Entry Agreements and Funding for Expensive Therapies

Author:   Mondher Toumi (Professor of Public Health at Aix-Marseille University, France) ,  Szymon Jarosławski
Publisher:   Taylor & Francis Ltd
ISBN:  

9780367500269


Pages:   159
Publication Date:   24 June 2022
Format:   Paperback
Availability:   In Print   Availability explained
This item will be ordered in for you from one of our suppliers. Upon receipt, we will promptly dispatch it out to you. For in store availability, please contact us.

Our Price $105.00 Quantity:  
Add to Cart

Share |

Managed Entry Agreements and Funding for Expensive Therapies


Add your own review!

Overview

Full Product Details

Author:   Mondher Toumi (Professor of Public Health at Aix-Marseille University, France) ,  Szymon Jarosławski
Publisher:   Taylor & Francis Ltd
Imprint:   CRC Press
Weight:   0.420kg
ISBN:  

9780367500269


ISBN 10:   0367500264
Pages:   159
Publication Date:   24 June 2022
Audience:   College/higher education ,  Professional and scholarly ,  Tertiary & Higher Education ,  Professional & Vocational
Format:   Paperback
Publisher's Status:   Active
Availability:   In Print   Availability explained
This item will be ordered in for you from one of our suppliers. Upon receipt, we will promptly dispatch it out to you. For in store availability, please contact us.

Table of Contents

"1. Introduction to Managed Entry Agreements 2. Definition and Classification of MEAs 3. From Coverage with Evidence Development to Individual Performance-Based Agreements in Italy 4. Coverage with Evidence Development for Multiple Sclerosis Drugs in the UK: A ""Costly Failure""? 5. Country Comparison of the Implementation of Managed Entry Agreements 6. Novel Funding Models for Expensive Therapies 7. Managed Entry Agreement for Cell and Gene Therapies"

Reviews

Author Information

Mondher Toumi is M.D. by training, M.Sc. in Biostatistics, and in Biological Sciences (option pharmacology) and Ph.D. in Economic Sciences. Mondher Toumi is Professor of Public Health at Aix-Marseille University. After working for 12 years as Research Manager in the department of pharmacology at the University of Marseille, he joined the Public Health Department in 1993. In 1995 he embraces a carrier in the pharmaceutical industry for 13 years. Toumi was appointed Global Vice President at Lundbeck A/S in charge of health economics, outcome research, pricing, market access, epidemiology, risk management, governmental affairs and competitive intelligence. In 2008, he founded Creativ-Ceutical, an international consulting firm dedicated to support health industries and authorities in strategic decision-making. In February 2009 he was appointed Professor at Lyon I University in the Department of Decision Sciences and Health Policies. The same year, he was appointed Director of the Chair of Public Health and Market Access. He launched the first European University Diploma of Market Access (EMAUD) an international course already followed by almost 350 students. Additionally, he recently created the Market Access Society to promote education, research and scientific activities at the interface of market access, HTA, public health and health economic assessment. He is editor in Chief of the Journal of Market Access and Health Policy (JMAHP) which was just granted PubMed indexation. Toumi is also visiting Professor at Beijing University (Third Hospital). He is a recognized expert in health economics and an authority on market access and risk management. He has more than 250 scientific publications and communications, and has contributed to several books.

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions
Latest Reading Guide

wl

Shopping Cart
Your cart is empty
Shopping cart
Mailing List